The impact of gene therapy on T cell function in cancer

Human Gene Therapy
K S Zier, B Gansbacher

Abstract

Studies of signal transduction by T cells are slowly identifying the intracellular messengers that must be generated for full T cell activation to take place. The recent, convincing identification of several tumor-associated antigens (TAA) has transformed our task into trying to define the mechanisms that underlie the failure of T cells to destroy antigenic tumor cells. Although there are a variety of hypotheses that explain why tumors grow progressively, even if they are antigenic, recent evidence suggests that T cells from tumor-bearing patients exhibit abnormalities in signal transduction that render them unable to respond to appropriate activation signals, even following proper stimulation. Gene therapy with interleukin-2 (IL-2)-secreting tumor cells in an animal model has been effective in preventing the onset of these signaling defects. Discovery of the molecular mechanisms by which such cytokine-secreting tumor cells induce immune responses and how they may best be applied clinically may provide clearer indications of the directions to pursue to alter the balance between the T cell and the tumor cell in the patient's favor.

References

Dec 7, 1978·The New England Journal of Medicine·S Broder, T A Waldmann
Oct 1, 1992·Current Opinion in Immunology·M J Browning, W F Bodmer
May 14, 1992·Nature·T J MolinaA Veillette
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C E RuddS F Schlossman
Jan 1, 1989·International Reviews of Immunology·A J George, F K Stevenson
Mar 1, 1994·The Journal of Experimental Medicine·K E TruittJ B Imboden
Jul 1, 1994·Immunology Today·C H JuneC B Thompson
Jan 1, 1993·Advances in Cancer Research·D Sulitzeanu
Jun 1, 1993·The Journal of Experimental Medicine·F A Harding, J P Allison
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BaskarL H Glimcher
Jun 1, 1993·Current Opinion in Immunology·M K Jenkins, J G Johnson
Dec 15, 1994·International Journal of Cancer. Journal International Du Cancer·F FaraceF Triebel
Jul 1, 1994·The Journal of Experimental Medicine·A N Houghton
Jan 1, 1994·Annual Review of Immunology·T BoonA Van Pel
Jun 2, 1994·Nature·D M Pardoll
Oct 1, 1993·Annals of Surgery·S A RosenbergS E Ettinghausen
Oct 1, 1993·Current Opinion in Immunology·C J Melief, W M Kast
Jan 28, 1994·Cell·A Weiss, D R Littman
May 14, 1993·Science·R C Mulligan

❮ Previous
Next ❯

Citations

Jan 1, 1996·Springer Seminars in Immunopathology·H Chong, R G Vile
Jan 11, 2001·Journal of Immunological Methods·K V BromelowB E Souberbielle
Mar 1, 1996·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·K S Zier, B Gansbacher
Oct 1, 1995·Annals of Medicine·C H Evans, P D Robbins
Oct 30, 2004·The Journal of Gene Medicine·Karim El BakkouriAnnick Brandenburger
Mar 21, 2001·Biotechnology & Genetic Engineering Reviews·M G GilliganP F Searle
Jul 31, 1998·Hematology/oncology Clinics of North America·S M DubinettR K Batra

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.